Braskem Controllers Counter Creditors' $3B Injection Demand

Braskem's controlling shareholders are preparing a counterproposal to creditors' demand for a $3 billion capital injection, which they deem excessive relative to the company's market value. Negotiations are ongoing, with a counterproposal being finalized. The outcome will determine Braskem's financial restructuring path and could impact its creditworthiness and equity value.